Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets

Zaid, Abdel Naser; Assali, Mohyeddin; Qaddomi, Aiman; Ghanem, Mashhour; Zaaror, Yara Abu

Abstract

Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets

Author(s): Zaid Abdel Naser, Assali Mohyeddin, Qaddomi Aiman, Ghanem Mashhour, Zaaror Yara Abu

Issue: Mar/Apr 2014 - Volume 18, Number 2

View All Articles in Issue

Page(s): 169-174

Download in electronic PDF format for $75

Abstract

The aim of this study was to develop an extemporaneous valsartan suspension (80 mg valsartan/ 5 mL) starting from commercial tablets (80-mg/ tablet). A high-performance liquid chromatographic system was used for the analysis and quantification of valsartan in the samples studied. Samples of valsartan suspension for analysis were prepared as reported by the validated high-performance liquid chromatographic method and the dissolution tests were performed according to the U.S. Food and Drug Administration’s method. The high-performance liquid chromatographic assay indicated that the 80-mg/5-mL valsartan suspension was stable for 30 days when stored at long-term and accelerated storage conditions. Valsartan release profile showed that approximately 85% of valsartan dissolved after 10 minutes and, accordingly, the calculation of similarity factor was not necessary. It is possible for the pharmacist to crush valsartan 80-mg tablets and prepare a suspension which has dosage flexibility that can be calculated according to body-surface area, kidney, and liver functions, without affecting the chemical stability of the active ingredient nor its dissolution profile and also have a cost-effective dosage form.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Mar/Apr 2014 Pg. 169-174	Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets Author(s): Zaid Abdel Naser, Assali Mohyeddin, Qaddomi Aiman, Ghanem Mashhour, Zaaror Yara Abu
May/Jun 2003 Pg. 233-239	Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets Author(s): Kaila Nitin, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
Sep/Oct 2003 Pg. 389-393	Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride Author(s): Alexander Kenneth S, Thyangarajapuram N
Mar/Apr 2016 Pg. 159-163	Stability of Commercially Available Grape and Compounded Cherry Oral Vancomycin Preparations Stored in Syringes and Cups Author(s): Kirk Loren, Lewis Paul, Luu Yao, Brown Stacy
May/Jun 2018 Pg. 247-251	Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations Author(s): Visser J Carolina, ten Seldam Inge E J, van der Linden Isabella J, Hinrichs Wouter L J, Veenendaal Reinier F H, Dijkers Eli C F, Woerdenbag Herman J
Jan/Feb 2023 Pg. 72-77	Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base Author(s): Spennacchio Antonio, Lopedota Angela, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
Jul/Aug 2020 Pg. 327-336	Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Jul/Aug 2008 Pg. 372-374	Chemical Stability of Perphenazine in Two Commercially Available Vehicles for Oral Liquid Dosage Forms Author(s): Gupta Vishnu D
May/Jun 2019 Pg. 237	Valsartan 16-mg/mL Oral Suspension Author(s): Allen Loyd V Jr
Jul/Aug 2010 Pg. 342-345	Evaluation of Extemporaneous Oral Itraconazole Suspensions by Dissolution Profiles Mapping Author(s): Tong Henry H Y, Chan Hokman, Du Zhen, Zheng Ying
Mar/Apr 2017 Pg. 160-163	Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions Author(s): Kabiche Djamila, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
Jul/Aug 2017 Pg. 322-329	Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox) Author(s): Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
Sep/Oct 2021 Pg. 431-439	Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt Author(s): Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
Mar/Apr 1997 Pg. 128-131	Stability of Allopurinol Suspension Compounded from Tablets Author(s): Alexander Kenneth S, Davar Nipun, Parker Gordon A
Jan/Feb 2018 Pg. 66-75	Stability of an Alcohol-free, Dye-free Hydrocortisone (2 mg/mL) Compounded Oral Suspension Author(s): Manchanda Arushi, Laracy Melissa, Savji Taslim, Bogner Robin H
Jan/Feb 2001 Pg. 9-12	Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients Author(s): Schotik Debora
Sep/Oct 2018 Pg. 433-439	Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding Author(s): Zhao Fang, Dave Vivek S, Mar Mazin Z, Perri Jonathan R
Sep/Oct 2006 Pg. 396-399	Temozolomide Stability in Extemporaneously Compounded Oral Suspensions Author(s): Trissel Lawrence A, Zhang Yanping, Koontz Susannah E
Jul/Aug 2021 Pg. 329	Valsartan 4-mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Nov/Dec 2021 Pg. 523-527	Formulation, Physical Stability, and the Clinical Effectiveness of Extemporaneous Ivermectin Oral Solution Author(s): Zaid Abdel-Naser, Zaaror Yara Abu, Qaddumi Aiman, Ratrout Ala, Ahmad Ayda, Hamad Emad, Kittana Naim